“Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting”, Swiss Med Wkly, vol. 139, no. 1112, pp. 173–173, Mar. 2009, doi: 10.4414/smw.2009.12381.